董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yat Gai Au | 男 | Chairman of the Board and Chief Executive Officer and Director | 54 | 未披露 | 43789.61 | 2026-10-07 |
| James Wai Hong Chung | 男 | Chief Operating Officer and Chief Strategy Officer and Director | 49 | 13.87万美元 | 1184.43 | 2026-10-07 |
| Evana Yee Wah Hui | 女 | Independent Director | 54 | 未披露 | 未持股 | 2026-10-07 |
| Margaret Hoor Han Lo | 女 | Independent Director | 66 | 未披露 | 未持股 | 2026-10-07 |
| Wing Yan Lo | 男 | Independent Director | 65 | 未披露 | 未持股 | 2026-10-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yat Gai Au | 男 | Chairman of the Board and Chief Executive Officer and Director | 54 | 未披露 | 43789.61 | 2026-10-07 |
| James Wai Hong Chung | 男 | Chief Operating Officer and Chief Strategy Officer and Director | 49 | 13.87万美元 | 1184.43 | 2026-10-07 |
| Yat Pui Au | 男 | Chief Business Officer | 52 | 未披露 | 未持股 | 2026-10-07 |
| Michelle Chan | 女 | Principal Financial Officer | -- | 未披露 | 未持股 | 2026-10-07 |
董事简历
中英对照 | 中文 | 英文- Yat Gai Au
-
Yat Gai Au是脑再生科技控股有限公司的首席执行官，自2014年起担任脑再生科技控股有限公司的董事。他的职业生涯始于德意志银行和ING Barings的投资银行业务，是1998年至1999年期间在亚洲赢得年度并购交易奖项的核心团队成员之一，其中包括价值超过40亿美元的交易。他是一位活跃的房地产、科技和生物技术投资者。他为香港和美国的数千个贫困家庭和老人资助并参与了多项慈善活动。在新冠疫情爆发期间，他向医院、老年人和困难家庭捐赠了超过20万个口罩。2018年9月，区先生成立了Regencell Foundation Limited，以推进他的慈善事业。区先生毕业于加州大学伯克利分校，获得哈斯商学院理学学士学位。
Yat Gai Au is Regencell Bioscience Holdings Limited's Chief Executive Officer and has been Regencell Bioscience Holdings Limited's director since 2014. He began his career in investment banking at Deutsche Bank and ING Barings and was one of the core team members that won Merger and Acquisitions deal of the year awards in Asia from 1998 to 1999 comprising over $4 billion worth of deals. He is an active property, technology and biotech investor. He funds and participates in several charity events for thousands of underprivileged families and elderlies in Hong Kong and the U.S. During the COVID 19 outbreak, he donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au set up Regencell Foundation Limited to further his charitable endeavors. Mr. Au graduated from University of California, Berkeley with a Bachelor of Science degree from the Haas School of Business. - Yat Gai Au是脑再生科技控股有限公司的首席执行官，自2014年起担任脑再生科技控股有限公司的董事。他的职业生涯始于德意志银行和ING Barings的投资银行业务，是1998年至1999年期间在亚洲赢得年度并购交易奖项的核心团队成员之一，其中包括价值超过40亿美元的交易。他是一位活跃的房地产、科技和生物技术投资者。他为香港和美国的数千个贫困家庭和老人资助并参与了多项慈善活动。在新冠疫情爆发期间，他向医院、老年人和困难家庭捐赠了超过20万个口罩。2018年9月，区先生成立了Regencell Foundation Limited，以推进他的慈善事业。区先生毕业于加州大学伯克利分校，获得哈斯商学院理学学士学位。
- Yat Gai Au is Regencell Bioscience Holdings Limited's Chief Executive Officer and has been Regencell Bioscience Holdings Limited's director since 2014. He began his career in investment banking at Deutsche Bank and ING Barings and was one of the core team members that won Merger and Acquisitions deal of the year awards in Asia from 1998 to 1999 comprising over $4 billion worth of deals. He is an active property, technology and biotech investor. He funds and participates in several charity events for thousands of underprivileged families and elderlies in Hong Kong and the U.S. During the COVID 19 outbreak, he donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au set up Regencell Foundation Limited to further his charitable endeavors. Mr. Au graduated from University of California, Berkeley with a Bachelor of Science degree from the Haas School of Business.
- James Wai Hong Chung
-
James Wai Hong Chung自2023年12月28日起担任脑再生科技控股有限公司的董事，自2021年8月起担任脑再生科技控股有限公司的首席运营官（“COO”），自2020年10月起担任首席战略官。自2015年7月起加入脑再生科技有限公司，担任高级副总裁。他带来了15年的各种主演经验。在加入Regencell之前，钟先生在投资科技股份管理亚洲股票和衍生品电子交易平台，在那里他获得了丰富的银行和金融经验。在此之前，他曾任职于Sungard Financial Systems，为银行提供从前到后的交易和风险管理软件解决方案。在一家初创对冲基金IT咨询公司工作时，他还获得了从销售和会计管理、项目管理、技术和商业分析师等不同角色的经验。钟先生的职业生涯始于和记环球电讯的电信工程师，最终领导了一个小型工程师团队。Chung先生毕业于斯坦福大学管理科学与工程系量化金融学和不列颠哥伦比亚理工学院电信技术专业。
James Wai Hong Chung has been Regencell Bioscience Holdings Limited's director since December 28, 2023, Regencell Bioscience Holdings Limited's Chief Operating Officer ("COO") since August 2021 and Chief Strategy Officer since October 2020. He has joined Regencell Bioscience Limited as senior vice president since July 2015.Prior to joining Regencell, Mr. Chung managed the Asia equities and derivatives electronic trading platform at Investment Technology Group, where he gained extensive banking and finance experience. Prior to that, he worked at Sungard Financial Systems, providing front to back trading and risk management software solutions for banks. He also gained experiences in different roles from sales and accounting management, project management, technology and business analyst when he worked at a startup hedge fund IT consulting business. Mr. Chung started his career as a telecommunication engineer at Hutchison Global Crossing and eventually led a small team of engineers. Mr. Chung is a graduate of Quantitative Finance from the Management Science and Engineering Department at Stanford University and Telecommunications Technology from British Columbia Institute of Technology. - James Wai Hong Chung自2023年12月28日起担任脑再生科技控股有限公司的董事，自2021年8月起担任脑再生科技控股有限公司的首席运营官（“COO”），自2020年10月起担任首席战略官。自2015年7月起加入脑再生科技有限公司，担任高级副总裁。他带来了15年的各种主演经验。在加入Regencell之前，钟先生在投资科技股份管理亚洲股票和衍生品电子交易平台，在那里他获得了丰富的银行和金融经验。在此之前，他曾任职于Sungard Financial Systems，为银行提供从前到后的交易和风险管理软件解决方案。在一家初创对冲基金IT咨询公司工作时，他还获得了从销售和会计管理、项目管理、技术和商业分析师等不同角色的经验。钟先生的职业生涯始于和记环球电讯的电信工程师，最终领导了一个小型工程师团队。Chung先生毕业于斯坦福大学管理科学与工程系量化金融学和不列颠哥伦比亚理工学院电信技术专业。
- James Wai Hong Chung has been Regencell Bioscience Holdings Limited's director since December 28, 2023, Regencell Bioscience Holdings Limited's Chief Operating Officer ("COO") since August 2021 and Chief Strategy Officer since October 2020. He has joined Regencell Bioscience Limited as senior vice president since July 2015.Prior to joining Regencell, Mr. Chung managed the Asia equities and derivatives electronic trading platform at Investment Technology Group, where he gained extensive banking and finance experience. Prior to that, he worked at Sungard Financial Systems, providing front to back trading and risk management software solutions for banks. He also gained experiences in different roles from sales and accounting management, project management, technology and business analyst when he worked at a startup hedge fund IT consulting business. Mr. Chung started his career as a telecommunication engineer at Hutchison Global Crossing and eventually led a small team of engineers. Mr. Chung is a graduate of Quantitative Finance from the Management Science and Engineering Department at Stanford University and Telecommunications Technology from British Columbia Institute of Technology.
- Evana Yee Wah Hui
-
Evana Yee Wah Hui自2021年7月起担任脑再生科技控股有限公司的独立董事及审计委员会、薪酬委员会和提名与公司治理委员会成员。她拥有超过20年的零售和品牌管理经验。在泛亚领先的零售商Dairy Farm Company Limited的18年职业生涯中，她在区域和地方层面管理着业务的各个部门。她领导了覆盖九个市场的大中华区和亚洲地区的健康&婴儿品类的区域品类开发团队，实施门店布局/展示、品类开发和管理策略。此外，她还负责多个品类的销售和盈利，具有产品创建和开发、品牌建设、客户忠诚度等方面的经验。她还带头在香港推出了GNC和Boots两个品牌。在此之前，她在尼尔森花了三年时间开发和实施市场研究，她的主要客户包括联合利华、可口可乐、汇丰银行、默沙东和欧莱雅。许女士参与了慈善活动，例如在社区推广心理健康意识，并在香港医院管理局合办的当地高中举办研讨会，以促进自我意识和减少耻辱感。她拥有南加州大学MBA学位，毕业于米尔斯学院，获得文学学士、数学（荣誉）学位。
Evana Yee Wah Hui has been Regencell Bioscience Holdings Limited's independent director and member of audit committee, compensation committee and nominating and corporate governance committee since July 2021. She has over 20 years of retail and brand management experience. Throughout her 18 year career at the Dairy Farm Company Limited, a leading pan Asian retailer, she managed various segments of the business both at the regional and local level. She headed the regional category development team of the Health& Baby categories across the Greater China and Asian regions covering nine markets, implementing store layout/display, category development and management strategies. Furthermore, she was responsible for the sales and profitability of a diverse range of categories with experience in product creation and development, brand building, and customer loyalty. She also spearheaded the launch of both the GNC and Boots brands in Hong Kong. Prior to that, she spent three years developing and implementing market research at Nielsen, where her major clients included Unilever, Coca Cola, HSBC, MSD, and L'Oreal. Ms. Hui participated in charitable endeavors, such as promoting mental health awareness in the community and holding workshops to promote self awareness and reduce stigma in local high schools, co organized by the Hong Kong Hospital Authority. She holds an MBA from University of Southern California and graduated with a Bachelor of Arts, Mathematics (Honors) from Mills College. - Evana Yee Wah Hui自2021年7月起担任脑再生科技控股有限公司的独立董事及审计委员会、薪酬委员会和提名与公司治理委员会成员。她拥有超过20年的零售和品牌管理经验。在泛亚领先的零售商Dairy Farm Company Limited的18年职业生涯中，她在区域和地方层面管理着业务的各个部门。她领导了覆盖九个市场的大中华区和亚洲地区的健康&婴儿品类的区域品类开发团队，实施门店布局/展示、品类开发和管理策略。此外，她还负责多个品类的销售和盈利，具有产品创建和开发、品牌建设、客户忠诚度等方面的经验。她还带头在香港推出了GNC和Boots两个品牌。在此之前，她在尼尔森花了三年时间开发和实施市场研究，她的主要客户包括联合利华、可口可乐、汇丰银行、默沙东和欧莱雅。许女士参与了慈善活动，例如在社区推广心理健康意识，并在香港医院管理局合办的当地高中举办研讨会，以促进自我意识和减少耻辱感。她拥有南加州大学MBA学位，毕业于米尔斯学院，获得文学学士、数学（荣誉）学位。
- Evana Yee Wah Hui has been Regencell Bioscience Holdings Limited's independent director and member of audit committee, compensation committee and nominating and corporate governance committee since July 2021. She has over 20 years of retail and brand management experience. Throughout her 18 year career at the Dairy Farm Company Limited, a leading pan Asian retailer, she managed various segments of the business both at the regional and local level. She headed the regional category development team of the Health& Baby categories across the Greater China and Asian regions covering nine markets, implementing store layout/display, category development and management strategies. Furthermore, she was responsible for the sales and profitability of a diverse range of categories with experience in product creation and development, brand building, and customer loyalty. She also spearheaded the launch of both the GNC and Boots brands in Hong Kong. Prior to that, she spent three years developing and implementing market research at Nielsen, where her major clients included Unilever, Coca Cola, HSBC, MSD, and L'Oreal. Ms. Hui participated in charitable endeavors, such as promoting mental health awareness in the community and holding workshops to promote self awareness and reduce stigma in local high schools, co organized by the Hong Kong Hospital Authority. She holds an MBA from University of Southern California and graduated with a Bachelor of Arts, Mathematics (Honors) from Mills College.
- Margaret Hoor Han Lo
-
Margaret Hoor Han Lo自2025年6月起担任脑再生科技控股有限公司的独立董事及审计委员会、薪酬委员会和提名与公司治理委员会成员。卢女士是一位经验丰富的投资者，在房地产投资领域拥有超过30年的丰富经验。她也深深投身于慈善事业，积极参与各种慈善倡议和志愿者工作。
Margaret Hoor Han Lo has been Regencell Bioscience Holdings Limited's independent director and member of audit committee, compensation committee and nominating and corporate governance committee since June 2025. Ms. Lo is a seasoned investor with over 30 years of extensive experience in the real estate investments. She is also deeply committed to philanthropy, actively participating in various charitable initiatives and volunteer work. - Margaret Hoor Han Lo自2025年6月起担任脑再生科技控股有限公司的独立董事及审计委员会、薪酬委员会和提名与公司治理委员会成员。卢女士是一位经验丰富的投资者，在房地产投资领域拥有超过30年的丰富经验。她也深深投身于慈善事业，积极参与各种慈善倡议和志愿者工作。
- Margaret Hoor Han Lo has been Regencell Bioscience Holdings Limited's independent director and member of audit committee, compensation committee and nominating and corporate governance committee since June 2025. Ms. Lo is a seasoned investor with over 30 years of extensive experience in the real estate investments. She is also deeply committed to philanthropy, actively participating in various charitable initiatives and volunteer work.
- Wing Yan Lo
-
Wing Yan Lo，自2021年12月起担任脑再生科技控股有限公司独立董事及审计委员会、薪酬委员会和提名与公司治理委员会成员。拥有超过三十年的生物制药、学术医学、公司治理、战略咨询经验。Lo博士毕业于剑桥大学，获得药理学哲学硕士学位和分子神经科学博士学位。Lo博士的职业生涯始于麦肯锡公司，担任管理顾问，曾在中国联通（香港）、香港电讯、花旗银行HK、I.T Limited、南华传媒集团和Kidsland International Holdings Limited担任高级职务。Lo博士目前担任多家香港联合交易所有限公司（“香港联交所”）主板上市公众公司的独立非执行董事；Lo博士是电视广播有限公司（香港联交所股份代号：511）、OCI International Holdings Limited（香港联交所股份代号：329）、CSI Properties Limited（香港联交所股份代号：497）、Jingrui Holdings Limited（香港联交所股份代号：1862）、Oshidori International Holdings Limited（香港联交所股份代号：622）的独立非执行董事。Lo博士还是南太地产公司（纽约证券交易所股票代码：NTP）的独立非执行董事，该公司以前在纽约证券交易所（“NYSE”）上市。Lo博士获委任为香港特别行政区政府太平绅士（JP），是Charles K. Kao阿尔茨海默病基金会和ISF学院的创会理事，也是Junior Achievement HK的现任主席。
Wing Yan Lo has been Regencell Bioscience Holdings Limited's independent director and member of audit committee, compensation committee and nominating and corporate governance committee since December 2021. He has over three decades of biopharma, academic medicine, corporate governance, and strategic advisory experience. Dr. Lo graduated from Cambridge University with a Master of Philosophy Degree in Pharmacology and a Ph.D. Degree in Molecular Neuroscience. Dr. Lo started his career in McKinsey & Company Inc. as a management consultant and held senior positions in China Unicom, Hongkong Telecom, Citibank HK, I.T Limited, South China Media Group and Kidsland International Holdings Limited in the past. Dr. Lo currently serves as an independent non executive director of a number of public companies listed on the Main Board of The Stock Exchange of Hong Kong Limited ("HKSE"); Dr. Lo is an independent non executive director of Television Broadcasts Ltd (HKSE stock code: 511),CWT International Limited (HKSE stock code: 521) and NetDragon WebSoft Holdings Limited (HKSE stock code: 777). Dr. Lo was appointed a Justice of Peace of the Government of the Hong Kong Special Administrative Region. He holds the position of chairman and founding governor of the Charles K. Kao Foundation for Alzheimer's Disease, serves as the founding governor of ISF Academy, and is the chairman of Junior Achievement HK. - Wing Yan Lo，自2021年12月起担任脑再生科技控股有限公司独立董事及审计委员会、薪酬委员会和提名与公司治理委员会成员。拥有超过三十年的生物制药、学术医学、公司治理、战略咨询经验。Lo博士毕业于剑桥大学，获得药理学哲学硕士学位和分子神经科学博士学位。Lo博士的职业生涯始于麦肯锡公司，担任管理顾问，曾在中国联通（香港）、香港电讯、花旗银行HK、I.T Limited、南华传媒集团和Kidsland International Holdings Limited担任高级职务。Lo博士目前担任多家香港联合交易所有限公司（“香港联交所”）主板上市公众公司的独立非执行董事；Lo博士是电视广播有限公司（香港联交所股份代号：511）、OCI International Holdings Limited（香港联交所股份代号：329）、CSI Properties Limited（香港联交所股份代号：497）、Jingrui Holdings Limited（香港联交所股份代号：1862）、Oshidori International Holdings Limited（香港联交所股份代号：622）的独立非执行董事。Lo博士还是南太地产公司（纽约证券交易所股票代码：NTP）的独立非执行董事，该公司以前在纽约证券交易所（“NYSE”）上市。Lo博士获委任为香港特别行政区政府太平绅士（JP），是Charles K. Kao阿尔茨海默病基金会和ISF学院的创会理事，也是Junior Achievement HK的现任主席。
- Wing Yan Lo has been Regencell Bioscience Holdings Limited's independent director and member of audit committee, compensation committee and nominating and corporate governance committee since December 2021. He has over three decades of biopharma, academic medicine, corporate governance, and strategic advisory experience. Dr. Lo graduated from Cambridge University with a Master of Philosophy Degree in Pharmacology and a Ph.D. Degree in Molecular Neuroscience. Dr. Lo started his career in McKinsey & Company Inc. as a management consultant and held senior positions in China Unicom, Hongkong Telecom, Citibank HK, I.T Limited, South China Media Group and Kidsland International Holdings Limited in the past. Dr. Lo currently serves as an independent non executive director of a number of public companies listed on the Main Board of The Stock Exchange of Hong Kong Limited ("HKSE"); Dr. Lo is an independent non executive director of Television Broadcasts Ltd (HKSE stock code: 511),CWT International Limited (HKSE stock code: 521) and NetDragon WebSoft Holdings Limited (HKSE stock code: 777). Dr. Lo was appointed a Justice of Peace of the Government of the Hong Kong Special Administrative Region. He holds the position of chairman and founding governor of the Charles K. Kao Foundation for Alzheimer's Disease, serves as the founding governor of ISF Academy, and is the chairman of Junior Achievement HK.
高管简历
中英对照 | 中文 | 英文- Yat Gai Au
Yat Gai Au是脑再生科技控股有限公司的首席执行官，自2014年起担任脑再生科技控股有限公司的董事。他的职业生涯始于德意志银行和ING Barings的投资银行业务，是1998年至1999年期间在亚洲赢得年度并购交易奖项的核心团队成员之一，其中包括价值超过40亿美元的交易。他是一位活跃的房地产、科技和生物技术投资者。他为香港和美国的数千个贫困家庭和老人资助并参与了多项慈善活动。在新冠疫情爆发期间，他向医院、老年人和困难家庭捐赠了超过20万个口罩。2018年9月，区先生成立了Regencell Foundation Limited，以推进他的慈善事业。区先生毕业于加州大学伯克利分校，获得哈斯商学院理学学士学位。
Yat Gai Au is Regencell Bioscience Holdings Limited's Chief Executive Officer and has been Regencell Bioscience Holdings Limited's director since 2014. He began his career in investment banking at Deutsche Bank and ING Barings and was one of the core team members that won Merger and Acquisitions deal of the year awards in Asia from 1998 to 1999 comprising over $4 billion worth of deals. He is an active property, technology and biotech investor. He funds and participates in several charity events for thousands of underprivileged families and elderlies in Hong Kong and the U.S. During the COVID 19 outbreak, he donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au set up Regencell Foundation Limited to further his charitable endeavors. Mr. Au graduated from University of California, Berkeley with a Bachelor of Science degree from the Haas School of Business.- Yat Gai Au是脑再生科技控股有限公司的首席执行官，自2014年起担任脑再生科技控股有限公司的董事。他的职业生涯始于德意志银行和ING Barings的投资银行业务，是1998年至1999年期间在亚洲赢得年度并购交易奖项的核心团队成员之一，其中包括价值超过40亿美元的交易。他是一位活跃的房地产、科技和生物技术投资者。他为香港和美国的数千个贫困家庭和老人资助并参与了多项慈善活动。在新冠疫情爆发期间，他向医院、老年人和困难家庭捐赠了超过20万个口罩。2018年9月，区先生成立了Regencell Foundation Limited，以推进他的慈善事业。区先生毕业于加州大学伯克利分校，获得哈斯商学院理学学士学位。
- Yat Gai Au is Regencell Bioscience Holdings Limited's Chief Executive Officer and has been Regencell Bioscience Holdings Limited's director since 2014. He began his career in investment banking at Deutsche Bank and ING Barings and was one of the core team members that won Merger and Acquisitions deal of the year awards in Asia from 1998 to 1999 comprising over $4 billion worth of deals. He is an active property, technology and biotech investor. He funds and participates in several charity events for thousands of underprivileged families and elderlies in Hong Kong and the U.S. During the COVID 19 outbreak, he donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au set up Regencell Foundation Limited to further his charitable endeavors. Mr. Au graduated from University of California, Berkeley with a Bachelor of Science degree from the Haas School of Business.
- James Wai Hong Chung
James Wai Hong Chung自2023年12月28日起担任脑再生科技控股有限公司的董事，自2021年8月起担任脑再生科技控股有限公司的首席运营官（“COO”），自2020年10月起担任首席战略官。自2015年7月起加入脑再生科技有限公司，担任高级副总裁。他带来了15年的各种主演经验。在加入Regencell之前，钟先生在投资科技股份管理亚洲股票和衍生品电子交易平台，在那里他获得了丰富的银行和金融经验。在此之前，他曾任职于Sungard Financial Systems，为银行提供从前到后的交易和风险管理软件解决方案。在一家初创对冲基金IT咨询公司工作时，他还获得了从销售和会计管理、项目管理、技术和商业分析师等不同角色的经验。钟先生的职业生涯始于和记环球电讯的电信工程师，最终领导了一个小型工程师团队。Chung先生毕业于斯坦福大学管理科学与工程系量化金融学和不列颠哥伦比亚理工学院电信技术专业。
James Wai Hong Chung has been Regencell Bioscience Holdings Limited's director since December 28, 2023, Regencell Bioscience Holdings Limited's Chief Operating Officer ("COO") since August 2021 and Chief Strategy Officer since October 2020. He has joined Regencell Bioscience Limited as senior vice president since July 2015.Prior to joining Regencell, Mr. Chung managed the Asia equities and derivatives electronic trading platform at Investment Technology Group, where he gained extensive banking and finance experience. Prior to that, he worked at Sungard Financial Systems, providing front to back trading and risk management software solutions for banks. He also gained experiences in different roles from sales and accounting management, project management, technology and business analyst when he worked at a startup hedge fund IT consulting business. Mr. Chung started his career as a telecommunication engineer at Hutchison Global Crossing and eventually led a small team of engineers. Mr. Chung is a graduate of Quantitative Finance from the Management Science and Engineering Department at Stanford University and Telecommunications Technology from British Columbia Institute of Technology.- James Wai Hong Chung自2023年12月28日起担任脑再生科技控股有限公司的董事，自2021年8月起担任脑再生科技控股有限公司的首席运营官（“COO”），自2020年10月起担任首席战略官。自2015年7月起加入脑再生科技有限公司，担任高级副总裁。他带来了15年的各种主演经验。在加入Regencell之前，钟先生在投资科技股份管理亚洲股票和衍生品电子交易平台，在那里他获得了丰富的银行和金融经验。在此之前，他曾任职于Sungard Financial Systems，为银行提供从前到后的交易和风险管理软件解决方案。在一家初创对冲基金IT咨询公司工作时，他还获得了从销售和会计管理、项目管理、技术和商业分析师等不同角色的经验。钟先生的职业生涯始于和记环球电讯的电信工程师，最终领导了一个小型工程师团队。Chung先生毕业于斯坦福大学管理科学与工程系量化金融学和不列颠哥伦比亚理工学院电信技术专业。
- James Wai Hong Chung has been Regencell Bioscience Holdings Limited's director since December 28, 2023, Regencell Bioscience Holdings Limited's Chief Operating Officer ("COO") since August 2021 and Chief Strategy Officer since October 2020. He has joined Regencell Bioscience Limited as senior vice president since July 2015.Prior to joining Regencell, Mr. Chung managed the Asia equities and derivatives electronic trading platform at Investment Technology Group, where he gained extensive banking and finance experience. Prior to that, he worked at Sungard Financial Systems, providing front to back trading and risk management software solutions for banks. He also gained experiences in different roles from sales and accounting management, project management, technology and business analyst when he worked at a startup hedge fund IT consulting business. Mr. Chung started his career as a telecommunication engineer at Hutchison Global Crossing and eventually led a small team of engineers. Mr. Chung is a graduate of Quantitative Finance from the Management Science and Engineering Department at Stanford University and Telecommunications Technology from British Columbia Institute of Technology.
- Yat Pui Au
Yat Pui Au自2023年2月起担任脑再生科技控股有限公司的首席商务官（“CBO”）。自2021年10月起加入脑再生科技有限公司，担任高级副总裁。他在战略管理和业务运营方面拥有超过24年的经验。在加入Regencell之前，他曾在实体安全和物业管理部门担任多个领导职务，在那里他实施了基于数字和云的客户关系管理解决方案，完成了政府/机构/私营部门的重大技术项目，并简化了营销、财务、IT、人力资源和运营部门的业务运营。Yat Pui Au先生的职业生涯始于美国计算机科学公司 IT/MIS集成和部署的顾问分析师。Yat Pui Au先生是Au先生的兄弟。他在加州大学伯克利分校获得法律研究学士学位。
Yat Pui Au has been Regencell Bioscience Holdings Limited's Chief Business Officer ("CBO") since February 2023. He has joined Regencell Bioscience Limited as senior vice president since October 2021. He has more than 24 years of experience in strategic management and business operations. Prior to joining Regencell, he worked at various leading roles in the physical security and property management sectors, where he implemented digital and cloud based Customer Relationship Management solutions, completed major technology projects for governmental/institutional/private sectors, and streamlined business operations across marketing, finance, IT, HR and operations departments. Mr. Yat Pui Au started his career as a consultant analyst for Computer Sciences Corporation for IT/MIS integrations and deployment.He obtained his Bachelor's degree in Legal Studies from UC Berkeley.- Yat Pui Au自2023年2月起担任脑再生科技控股有限公司的首席商务官（“CBO”）。自2021年10月起加入脑再生科技有限公司，担任高级副总裁。他在战略管理和业务运营方面拥有超过24年的经验。在加入Regencell之前，他曾在实体安全和物业管理部门担任多个领导职务，在那里他实施了基于数字和云的客户关系管理解决方案，完成了政府/机构/私营部门的重大技术项目，并简化了营销、财务、IT、人力资源和运营部门的业务运营。Yat Pui Au先生的职业生涯始于美国计算机科学公司 IT/MIS集成和部署的顾问分析师。Yat Pui Au先生是Au先生的兄弟。他在加州大学伯克利分校获得法律研究学士学位。
- Yat Pui Au has been Regencell Bioscience Holdings Limited's Chief Business Officer ("CBO") since February 2023. He has joined Regencell Bioscience Limited as senior vice president since October 2021. He has more than 24 years of experience in strategic management and business operations. Prior to joining Regencell, he worked at various leading roles in the physical security and property management sectors, where he implemented digital and cloud based Customer Relationship Management solutions, completed major technology projects for governmental/institutional/private sectors, and streamlined business operations across marketing, finance, IT, HR and operations departments. Mr. Yat Pui Au started his career as a consultant analyst for Computer Sciences Corporation for IT/MIS integrations and deployment.He obtained his Bachelor's degree in Legal Studies from UC Berkeley.
- Michelle Chan
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介